RESEARCH ARTICLE

Genetic Identification Is Critical for the Diagnosis of Parkinsonism: A Chinese Pedigree with Early Onset of Parkinsonism

Yang Yang¹, Bei-sha Tang¹,²,³,⁴, Ling Weng¹, Nan Li¹,³,⁴, Lu Shen¹,²,³,⁴, Jian Wang⁵, Chuanta Zuo⁶, Xin-xiang Yan¹,³,⁴, Kun Xia², Ji-feng Guo¹,²,³,⁴*

¹ Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People’s Republic of China, ² State Key Laboratory of Medical Genetics, Changsha, 410078, Hunan, People’s Republic of China, ³ Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, 410008, Hunan, People’s Republic of China, ⁴ Neurodegenerative Disorders Research Center, Central South University, Changsha, 410008, Hunan, People’s Republic of China, ⁵ Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, 200040, Shanghai, People’s Republic of China, ⁶ PET Center, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, 200040, Shanghai, People’s Republic of China

* guojifeng2003@163.com

Abstract

Background

A number of hereditary neurological diseases display indistinguishable features at the early disease stage. Parkinsonian symptoms can be found in numerous diseases, making it difficult to get a definitive early diagnosis of primary causes for patients with onset of parkinsonism. The accurate and early diagnosis of the causes of parkinsonian patients is important for effective treatments of these patients.

Methods

We have identified a Chinese family (82 family members over four generations with 21 affected individuals) that manifested the characterized symptoms of parkinsonism and was initially diagnosed as Parkinson’s disease. We followed up with the family for two years, during which we carried out clinical observations, Positron Emission Tomography-Computed Tomography neuroimaging analysis, and exome sequencing to correctly diagnose the case.

Results

During the two-year follow-up period, we performed comprehensive medical history collection, physical examination, and structural and functional neuroimaging studies of this Chinese family. We found that the patient exhibited progressive deteriorated parkinsonism with Parkinson disease-like neuropathology and also had a good response to the initial levodopa treatment. However, exome sequencing identified a missense mutation, N279K, in exon 10.
of \textit{MAPT} gene, verifying that the early parkinsonian symptoms in this family are caused by the genetic mutation for hereditary frontotemporal lobar dementia.

\section*{Conclusions}

For the inherited parkinsonian patients who even show the neuropathology similar to that in Parkinson’s disease and have initial response to levodopa treatment, genetic identification of the molecular basis for the disease is still required for defining the early diagnosis and correct treatment.

\section*{Introduction}

Parkinsonism is a neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability. In addition to drug- or toxin-induced parkinsonism, a wide range of diseases may lead to a similar set of symptoms, including Parkinson’s disease, parkinsonism-plus, Wilson’s disease, progressive supranuclear palsy, and a handful of other neurological conditions [1]. The fact that parkinsonism could be the only symptom in the early stage of numerous diseases makes it difficult to get a definitive early diagnosis for the primary causes of parkinsonism. However, as the disease progresses, some other significant characteristics of the symptoms would come forth; therefore, many diagnoses rely on the disease progression and close clinical observations for identifying the underlying causes of patients with parkinsonism. Although the fast development of functional neuroimaging technologies, including MRI, Positron Emission Tomography-Computed Tomograph (PET-CT) and single-photon emission CT (SPECT) provide us with high precision approaches that are required in modern clinical practice, the early diagnosis of Parkinsonian patients can be achieved by genetic identification of the gene mutations. Mutations in genes at more than 20 loci are known to cause genetic parkinsonism [2,3], however, the number of corresponding genes that need to be screened could be substantially high. Compared to the traditional candidate gene screening that is expensive and ineffective, the next generation sequencing methods, such as whole-genome sequencing and exome sequencing, should allow for readily identifying the genetic bases of Mendelian diseases.

Here we report the use of continued clinical observations, especially the functional neuroimaging studies, and the application of next generation sequencing methods to identify the genetic cause of a family with early parkinsonian symptoms.

\section*{Materials and Methods}

\subsection*{2.1 Subjects and Clinical Text}

The study was approved by the Ethics Committee of Xiangya Hospital affiliated to Central South University in China. Written informed consents were obtained from all subjects.

We collected a four-generation Chinese family (Fig 1) with parkinsonism, characterized by early onset, rapid progression, rigidity, hypokinesia, postural instability, and in some individuals, tremor. All the available affected individuals (5 patients, including 1 male and 4 female) were subjected to thorough neurological examinations by two or more experienced neurologists. Data from other family members were collected via interviews and available medical records of deceased patients. Genomic DNA was obtained from two groups of affected and unaffected individuals.
2.2 Neuroimaging

Magnetic Resonance Imaging (1.5T MRI scanner Signa GE, Milwaukee, USA) was performed in IV3 (proband) and IV20, and PET-CT imaging was carried out in IV1, IV3 and IV20. In MRI examination, the T1-weighted (T1W), T2-weighted (T2W) studies were available in our cases. $^{11}$C-CFT uptake studies and PD-related covariance pattern (PDRP) based on $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scans from IV1, IV3 and IV20 were performed in three-dimensional (3D) mode on a Siemens Biograph TruePoint PET•CT (Siemens healthcare, Munich, Bavaria, Germany), producing image slices over the whole brain with an intrinsic 3D resolution.

2.3 Exome Sequencing

Qualified genomic DNA samples were extracted from peripheral blood leucocytes of two affected members. The library preparation and exome sequencing, alignment of sequenced reads, single-nucleotide polymorphism and insertions or deletions calling, analysis for exome-sequencing results were processed as previously described [4].

2.4 Segregation Analysis

Seven variants predicted to be damaging, including exon 10 of the MAPT gene, were amplified by means of a polymerase-chain-reaction (PCR) assay and directly sequenced in all members of the study family.

Results

3.1 Clinical Presentations

The pedigree consisted of 82 family members over four generations, with 21 affected individuals, among which 5 patients were available (Fig 1). Static tremor on left lower limb was the initial symptom found in the right-handed proband (IV3) at age 39. She suffered from progressive bradykinesia and rigidity over trunk and left limb one year later, described as deteriorated ability of balance which led to occasional falls. Cramp in left lower limb started at the early stage of the disease. The diagnosis of “Parkinson’s disease” was made at the age of 41, and she was administered with levodopa in combination with benzerazide, piribedil, and benzhexol hydrochloride to which she responded well initially. When she was first admitted to our institute in 2008, at 42 years old, she presented with unilateral resting tremor, mild bradykinesia, rigidity.
exhibited in axial muscles, and postural instability, spared from speech or eye movement involvement. The UPDRS motor part was 10 points and MMSE score was 30 of 30 points (Table 1).

The proband was re-examined at 44 years old, in 2010. Her symptoms were deteriorated. Static tremor was still present, but had affected both lower extremities. Stiffness in the muscles of her neck, tongue and lower limb was conspicuous. Blurred vision was first demonstrated at the age of 43, accompanied by progressive visual acuity deterioration. Though described by her family as social withdrawal and apathy, she was still independent in most of her daily activities.

During examination, occasional drooling, paucity of facial expression and severely reduced blinking rate were observed. Absent vertical gaze and slow horizontal gaze were displayed, with discontinued horizontal nystagmus. Mutism was notable, as well as hypophonic voice. Muscle tone was increased, while muscle strength remained normal. Increased tendon reflexes were

Table 1. Clinical features in five affected members of the family.

| Sex | IV/3 | IV/4 | IV/5 | IV/7 | IV/20 |
|-----|------|------|------|------|------|
| Age at exam (yr) | 44 | 42 | 44 | 42 | 47 |
| Age at onset (yr) | 39 | 41 | 42 | 40 | 45 |
| Disease duration (yrs) | 5 | 1.5 | 2 | 2 | 2 |
| Initial symptoms | tremor | tremor | rigidity | rigidity | bradykinesia |
| Parkinsonism | | | | | |
| Bradykinesia | + | + | + | ± | ++ |
| Rigidity | + | ± | ++ | ++ | ++ |
| Tremor | + | + | + | - | + |
| Postural instability | ++ | + | ++ | + | + |
| Response to dopaminergic therapy | ++ | ++ | - | - | + |
| Personality changes | ++ | ++ | + | + | ++ |
| Dementia | ++ | + | ND | - | ++ |
| Eye movement abnormalities | ++ | + | ++ | - | - |
| Blurred vision | ++ | + | ++ | + | - |
| Nystagmus | + | - | - | - | - |
| Dysarthria | + | ± | ++ | ± | ++ |
| Mutism | ++ | - | + | - | ++ |
| Drooling | + | ± | + | - | + |
| Dystonia | + | + | - | - | - |
| Seizures | - | - | - | - | - |
| Ankle edema | - | - | - | - | +++ |
| Urinary incontinence | - | - | - | - | + |
| Tendon reflexes | N | + lower limbs | + upper limbs | + upper limbs | N |
| Babinski’s sign | + | ± | - | - | ± |
| Frontal lobe release sign | + | + | + | + | + |
| Cerebellar signs | - | - | - | - | - |
| UPDRS motor (part III) | 16 | 23 | ND | 13 | 54 |
| Webster Score | 7 | 10 | ND | 4 | 21 |
| MMSE | 29/30 | 30/30 | ND | 30/30 | 16/30 |
| WAIS-RC | Inferior to the bottom 5% of the population | Inferior to the bottom 20% of the population | ND | ND | ND |

Notes: Clinical signs are graded as follows: = absent, ± = subtle, + = mild, ++ = moderate, +++ = severe, | = increased, N = normal, D = defect, ND = not determined, UPDRS = Unified Parkinson’s Disease Rating Scale, WAIS-RC = Chinese Wechsler Intelligence Scale.

doi:10.1371/journal.pone.0136245.t001
obvious whereas Babinski sign was equivocal bilaterally. Frontal lobe release signs were present, including glabellar and palomental reflexes. UPDRS motor part was 16 points. She scored 29 of 30 points on the MMSE test, missing one point on the recall scales. However, the further Chinese Wechsler Intelligence Scale (WAIS-RC) showed that she scored in the bottom fifth percentile of the population.

The clinical features of the five available affected family members are summarized in Table 1. Adding data from the historical records of deceased patients, the age of onset of all patients in the family ranged from 39–48 years (mean 43.7 ± 2.9 years) and disease duration before death varied from 4–11 years (mean 7 ± 0.6 years). Parkinsonian features were illustrated as one of the most predominant initial symptoms in almost all patients. After onset, all affected individuals displayed a rapid progression. Personality changes, which included apathy, irritability, excessive adherence, disinhibition, were prominent in the early or middle stage, and worsened as disease developed. All patients showed postural instability and some were reported to exhibit positive Babinski sign. Supranuclear gaze palsy was presented in some affected individuals in the later stage. No record of cognitive functions of deceased patients was available, but some of these patients were recalled as having diminished memory by their families. WAIS-RC and MMSE of the proband and two other patients showed intellectual deficits.

3.2 Structural and Functional Neuroimaging Studies

The MRI scan of the proband at 42 years old demonstrated atrophy of the whole brain. It’s worth pointing out that the atrophy of frontotemporal lobe is most noticeable while the hippocampus is relatively unaffected (Fig 2A and 2B). In her second MRI scan, the results revealed the correspondent deterioration of patient’s condition, exhibiting the aggravated atrophy of frontotemporal lobe (Fig 2C–2F). Furthermore, we obtained the MRI image data from another family member IV20, who had very similar pattern of brain atrophy as well (Fig 2G and 2H). We also performed functional neuroimaging studies in the two patients. We performed the PET images via 11C-CFT in the pedigree, including one unaffected member IV1 and two patients IV3 and IV20 (Fig 3), and the results of the quantitative 11C-CFT uptake demonstrated that IV3 (Fig 3H) and IV20 (Fig 3I) exhibited significantly decreased uptake ratio of 11C-CFT in the striatum (specifically the caudate nucleus and putamen) compared with that of IV1 (Fig 3G), which was within the normal range (Table 2), indicating that the DAT availability of affected individuals was reduced in the nigrostriatal projection area. Furthermore, PDRP analysis via 18F-FDG PET (Fig 4) showed that in IV3, significant hypometabolism was identified in extensive prefrontal areas (Fig 4D), whereas hypermetabolism was found in the putamen, globus pallidum, cerebellum and sensorimotor cortex (Fig 4B and 4D) as compared with the normal member IV1 (Fig 4A and 4C). The overactivated regions were in accordance with the PDRP patterns found in Parkinson’s disease patients [5–7].

3.3 Genetic Variations Identified by Exome Sequencing

Exome sequencing was performed for the two affected individuals in the family (IV3, IV20 in Table 3). The quality of variations was controlled by the criteria previously established [4]. Using de novo assembly of exon sequences, we detected 114 coding insertions and 198 deletions. After identification of variants, we focused only on NS/SS/Indel (non-synonymous/donor site mutations and splicing/frameshift) variants which were more likely to be pathogenic mutations than other variants. Each sample was found to have at least a single NS/SS/Indel variant in ~6,900 candidate genes. Given that this is a rare disorder it is unlikely that the causative variants will be present in the general population, we compared our NS/SS/Indel variants to dbSNP129, eight previously exome-sequenced HapMap samples (‘HapMap 8’), and the SNP
release of the 1000 Genome Project (20100208 release) (Table 3), and removed the shared SNPs. Because parkinsonism in this family is autosomally dominantly inherited, all affected individuals should share the same causal variant, thus comparison of exome data from two samples (IV3, IV20) was performed and the candidate gene pool was downsized to 51 genes. Considering that most pathogenic variants affect highly conserved sequences and/or are predicted to be deleterious, we used PolyPhen to assess the flitted non-synonymous variants for a likely functional impact (Table 3). The functional prediction left only 21 variants to be further scanned (S1 Table), of which 7 can be expressed in the nervous system. In further segregation analyses, we used Sanger sequencing to screen for the 7 variants in all clinically affected subjects and eight presumptive unaffected family members in the family, and found that only the N279K missense mutation in MAPT, which has previously been reported to cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) [8–12], completely co-segregated with the phenotype in this family (Fig 5).

Discussion

Kindreds with FTDP-17 can be divided into the following two major clinical groups based on the phenotypes: dementia predominant and parkinsonism predominant [8]. Families in which dementia is the predominant form are more common, with the clinical features dominated by progressive dementia and personality changes, whereas familial forms with predominant parkinsonism are highly variable. The parkinsonism seen in FTD patients is usually characterized by akinetic-rigid syndrome but in some cases, patients may present symptoms of classical...
Parkinson’s diseases, atypical parkinsonism resembling progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS) [12,13]. The phenotype of the family described in this report was quite different from that of the dementia-predominant kindreds and shares more similarities with the parkinsonism-predominant phenotype at the early stage. Besides, the patients had good initial response to anti-parkinsonian drugs, which prompted an early misdiagnosis as

Fig 3. PET imaging of DATs via $^{11}$C-CFT in pedigree with p.N279K MAPT mutation. A–C: Axial positron emission tomographic images of $^{11}$C-CFT uptake in three family members. A, IV-1, B, IV-3, C, IV-20; D–F: The transverse CT in three family members, D, IV-1, E, IV-3, F, IV-20; G–I: Integrated imaging of Axial positron emission tomographic images and transverse CT in three family members, G, IV-1, H, IV-3, I, IV-20. The region with the highest signal intensity indicates the intake of $^{11}$C-CFT by regional dopamine transporter.

doi:10.1371/journal.pone.0136245.g003
“Parkinson’s disease” having not obtained detailed family history at first. However, as the disease progressed, psychiatric symptoms and personality changes began to appear, accompanied with pyramidal signs and cognitive impairments. All the above changes urged us to have the correct diagnosis of patients with early parkinsonian symptoms.

It has been a long time that PET brain imaging has been applied in detection of brain function under normal and disease conditions [14]. Specifically, glucose metabolism brain imaging using 18F-fluorodeoxyglucose (FDG) remains invaluable for differential diagnosis of patients with parkinsonism, who may display distinctive features of cerebral glucose metabolism due to

![Fig 4. PDRP via 18F-FDG in pedigree with p.N279K MAPT mutation.](image)

| Subject | Ratio | Caudate nucleus | Putamen(anterior) | Putamen(Posterior) |
|---------|-------|-----------------|-------------------|--------------------|
|         |       | Left | Right | Left | Right | Left | Right |
| IV-1    |       | 3.0  | 3.24  | 3.71 | 3.86  | 3.43 | 3.33  |
| IV-3    |       | 1.63 | 1.78  | 1.11 | 1.22  | 1.04 | 1.11  |
| IV-20   |       | 1.57 | 1.76  | 1.43 | 1.38  | 1.38 | 1.71  |
| Range of normal value |       | 2.51–3.41 | 3.22–4.26 | 3.11–4.05 |

doi:10.1371/journal.pone.0136245.t002

doi:10.1371/journal.pone.0136245.g004
different primary diseases that mimic the presentations of PD. Besides, the dopaminergic-specific radio-ligands have been developed to assist with differential diagnosis, such as $^{11}$C-CFT

![Fig 5. Sanger sequences of MAPT p.N279K mutation in this family. IV-3, IV-5, IV-20 are patients carrying the MAPT p.N279K mutation; IV-1, IV-6, IV-21, III-9, III-32 are unaffected family members.](image)

Table 3. Direct identification of the causal gene for the family by exome sequencing.

|                      | IV3          | IV20         | IV3 and IV20 shared |
|----------------------|--------------|--------------|---------------------|
| Ns/Indel/SV          | 32492        | 32417        | 15215               |
| Non-syn (missense/nonsense/splice sites/readthrough) | 6968 | 6991 | 3250 |
| Not in dbSNP 129     | 911          | 930          | 178                 |
| not in dbSNP129 nor Hapmap8 | 650  | 666  | 83   |
| not in dbSNP129 nor Hapmap8 nor 1000 genomes | 484 | 457  | 51   |
| Predicted to be deleterious | 206  | 203  | 21   |

Rows show the stepwise screening of the total non-synonymous/splice acceptor and donor site/insertions or deletions (NS/SS/Indel) to exclude those found in dbSNP129, the eight HapMap exomes, the dbSNP 1000 genomes, or all. Columns indicate the number of NS/SS/Indel variants observed in each affected individual (Columns 2–3) or both affected individuals (Columns 4) following exclusion criteria.

doi:10.1371/journal.pone.0136245.t003
[15], ¹¹C-raclopride [16], ¹¹C-DTBZ [17], ¹⁸F-dopa [18], which are involved in the presynaptic dopamine activities of dopamine transporter, dopamine receptors, vesicle transporter and dopamine storage, respectively. Although the imaging results could reveal distinctive atrophy in frontotemporal lobe combined with extensive prefrontal area hypometabolism and decreased metabolism in limited premotor and posterior parietal cortical regions, they cannot reach a definitive diagnosis of the disease causes.

According to the International consensus criteria for bvFTD [19], the patients in the pedigree meet the criteria for probable bvFTD, suggesting that we need to further explore the genetic changes in the pedigree to obtain a definitive genetic diagnosis. Thus, we performed exome sequencing for two affected individuals IV3 and IV20 and identified heterozygous mutations in the MAPT gene as the specific biological basis and the underlying cause of the disease in this family.

MAPT gene encodes microtubule-associated protein tau, which is abundant in the axons and stabilizes microtubules and promotes tubulin assembly into microtubules [20]. There are six tau isoforms detected in human brain. Alternative splicing of a 31-amino acid repeats located in the C terminus, which is encoded by exon 10 of the tau gene, results in three tau isoforms with 4 repeats (4R) each and the other three isoforms with 3 repeats (3R) each [21,22]. The 4R tau isoforms stabilize microtubules more strongly than the 3R tau [23]. Mutations in exon 10 of MAPT appear to cause disease by disrupting the alternative splicing of exon 10 and hence the ratio of 4R:3R tau [23]. Abnormal biological processes of tau protein have been associated with a series of neurodegenerative diseases, including AD, PSP, Pick’s disease, and other tauopathies.

So far, 38 mutations of MAPT have been reported to be associated with FTDP-17 [24]. The N279K missense mutation is the third most common FTDP-17 mutation, as it was described in five FTDP-17 families from USA, France, Italy and Japan, as well as two unrelated affected individuals from Japan [8–12]. Clinical analysis of previously reported patients suggested that the mutation leads to similar clinical patterns as were observed in this study. The average age at onset ranges from 40 to 50, and the average duration is 6–10 years. Parkinsonism is the first and prominent symptom, whereas at a later phase, symptoms include dementia, pyramidal dysfunction, supranuclear gaze palsy, personality changes, language difficulties or mutism, as well as myoclonus [10, 24].

To our knowledge, our study is the first report to genetically confirm FTDP-17 family in China with parkinsonian symptoms. Unlike previous reports, at least two patients in this family showed good initial response to levodopa for more than one year and three patients manifested typical resting tremor. Moreover, in the ¹¹C-CFT DAT and PDRP via ¹⁸F-FDG PET studies, patients were found to have decreased DAT availability and PD-like metabolic pattern, making the correct diagnosis of the disease quite difficult in the absence of molecular genetic diagnosis. Based on our study, a molecular genetic analysis is essential for the definitive diagnosis of patients with early parkinsonian symptoms.

Supporting Information
S1 Table. The bioinformatics of the 21 overlapping genes after filtration. (DOC)

Acknowledgments
Thank all the patients and controls for their participation in this study. This work was supported by grants from the Major State Basic Research Development Program of China (973 Program) (2011CB510001); National Natural Science Foundation of China (81430023,81130021, 81171198, 81371405, 81361120404, 81300980).
Author Contributions
Conceived and designed the experiments: YY BST LW JFG. Performed the experiments: YY LW NL JW CTZ. Analyzed the data: YY LW JW CTZ JFG. Contributed reagents/materials/analysis tools: BST LS CTZ XXY JFG. Wrote the paper: YY LW LS KX. Clinical inspection: NL XXY JFG.

References

1. Langston JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591–6. doi: 10.1002/ana.20834 PMID: 16566021

2. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010; 67: 1116–22. doi: 10.1001/archneurol.2010.194 PMID: 20837657

3. Fujioka S, Wszolek ZK. Update on genetics of parkinsonism. Neurodegener Dis 2012; 10: 257–60. doi: 10.1159/000334285 PMID: 22261420

4. Wang JL, Cao L, Li JH, Hu ZM, Li JD, Zhang JG, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 2011; 134: 3493–3501. doi: 10.1093/brain/awr289 PMID: 22120146

5. Wu P, Wang J, Peng S, Ma Y, Zhang H, Guan Y, Zuo C. Metabolic brain network in the Chinese patients with Parkinson’s disease based on 18F-FDG PET imaging. Parkinsonism Relat Disord 2013; 19: 622–7. doi: 10.1016/j.parkreldis.2013.02.013 PMID: 23529021

6. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130: 1834–46. doi: 10.1093/brain/awm086 PMID: 17470495

7. Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006; 129: 2667–78. doi: 10.1093/brain/awl162 PMID: 16844713

8. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA 1998; 95: 13103–13107. doi: 10.1073/pnas.95.22.13103 PMID: 9789048

9. Anima K, Kowalska A, Hasegawa M, Mukoyama M, Watanabe R, Kawai M, et al. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000; 54: 1787–1795. PMID: 10802785

10. Yasuda M, Kawamata T, Komure O, Kun o S, D’Souza I, Poorkaj P, et al. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 1999; 53: 864–868. PMID: 10489057

11. Tsuboi Y, Uitti RJ, Delisle MB, Ferreira JJ, Brefel-Courbon C, Rascol O, et al. Clinical features and disease haplotypes of individuals with the N279K tau gene mutation a comparison of the pallidopontonigral degeneration kindred and a French family. Arch Neurol 2002; 59: 943–50. doi: 10.1001/archneur.59.9.943 PMID: 12056930

12. Soliveri P, Rossi G, Monza D, Tagliavini F, Piacentini S, Albanese A, et al. A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Arch Neurol 2003; 60: 1454–6. doi: 10.1001/archneurol.60.10.1454 PMID: 14565081

13. Siuda J, Fujioka S, Wszolek ZK. Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism Relat Disord 2014; 20: 957–64. doi: 10.1016/j.parkreldis.2014.06.002 PMID: 24998994

14. NasraIIahl I, Dubroff J. An overview of PET neuroimaging. Semin Nucl Med 2013; 43: 449–61. doi: 10.1053/j.semnuclmed.2013.06.003 PMID: 24094712

15. Karimi M, Tian L, Brown CA, Flores HP, Loftin SK, Videen TO, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013; 73:390–6. doi: 10.1002/ana.23798 PMID: 23429393

16. Kim JY, Chung EJ, Lee WY, Shin HY, Lee GH, Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson’s disease; analysis of [11C]raclopride PET study. Mov Disord 2008; 23: 207–11. doi: 10.1002/mds.21787 PMID: 17999422

17. Kumar A, Mann S, Sossi V, Ruth TJ, Stoessl AJ, Schuizer M, Lee CS. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson‘’s disease. Brain 2003; 126: 2648–2655. doi: 10.1093/brain/awg270 PMID: 12937076
18. Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord 2009; 24: 2260–6. doi: 10.1002/mds.22817 PMID: 19845000

19. Piguet O, Homberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10: 162–172. doi: 10.1016/S1474-4422 (10)70299-4 PMID: 21147039

20. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002; 156: 1051–63. doi: 10.1083/jcb.20010805 PMID: 11901170

21. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats differential expression of tau protein mRNAs in human brain. EMBO J 1989; 8: 393–9. PMID: 2498079

22. Himmler A, Drechsel D, Kirchner MW, Martin DW Jr. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 1989; 9: 1381–8. doi: 10.1128/MCB.9.4.1381 PMID: 2498649

23. Levy SF, Leboeuf AC, Massie MR, Jordan MA, Wilson L, Feinstein SC. Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. J Biol Chem 2005; 280: 13520–8. doi: 10.1074/jbc.M413490200 PMID: 15671021

24. Wszolek ZK, Tsuboi Y, Ghetti B, Pickering-Brown S, Baba Y, Cheshire WP. Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet J Rare Dis 2006; 1: 30. doi: 10.1186/1750-1172-1-30 PMID: 16899117